Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Bryce A. Kerlin

Biography

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine. Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots. Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Academic and Clinical Areas

Pediatric Hemostasis-Thrombosis Fellowship

Program Director

Hemostasis and Thrombosis Center

Physician Team

Hematology/Oncology & BMT

Physician Team

Center for Clinical and Translational Research

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Awards, Honors & Organizations

Listed, Best Doctors in America

Research

Lab(s)

Center for Clinical and Translational Research

Publications

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

Professional Experience

2005 - Present Nationwide Children’s Hospital, Director of Hematology2004 - Present Nationwide Children’s Hospital Hemophilia & Bleeding Disorders Program, Director2004 - Present Ohio Bleeding Disorders Council, Board Member2004 - Present Nationwide Children’s Hospital, Pharmacy & Therapeutics2004 - Present Nationwide Children’s Hospital, Tumor Board2004 - 2004 Children’s Hospital of San Diego, Pharmacy & Therapeutics Committee2002 - 2004 San Diego Regional Pediatric Hemophilia Program, Director2002 - 2004 Children’s Hospital of San Diego, Tumor Board2002 - 2004 Children’s Hospital of San Diego, Cancer Committee2002 - 2004 Children’s Hospital of San Diego, Transfusion Medicine Committee2002 - 2004 Hemophilia Association of San Diego County, Medical Director1999 - 2002 Children’s Hospital of Wisconsin, Tumor Board1998 - 1999 Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Director1998 - 1999 House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Chairman

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Bryce A. Kerlin

Biography

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine. Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots. Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Academic and Clinical Areas

Pediatric Hemostasis-Thrombosis Fellowship

Program Director

Hemostasis and Thrombosis Center

Physician Team

Hematology/Oncology & BMT

Physician Team

Center for Clinical and Translational Research

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Awards, Honors & Organizations

Listed, Best Doctors in America

Research

Lab(s)

Center for Clinical and Translational Research

Publications

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Education

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

Professional Experience

2005 - Present Nationwide Children’s Hospital, Director of Hematology2004 - Present Nationwide Children’s Hospital Hemophilia & Bleeding Disorders Program, Director2004 - Present Ohio Bleeding Disorders Council, Board Member2004 - Present Nationwide Children’s Hospital, Pharmacy & Therapeutics2004 - Present Nationwide Children’s Hospital, Tumor Board2004 - 2004 Children’s Hospital of San Diego, Pharmacy & Therapeutics Committee2002 - 2004 San Diego Regional Pediatric Hemophilia Program, Director2002 - 2004 Children’s Hospital of San Diego, Tumor Board2002 - 2004 Children’s Hospital of San Diego, Cancer Committee2002 - 2004 Children’s Hospital of San Diego, Transfusion Medicine Committee2002 - 2004 Hemophilia Association of San Diego County, Medical Director1999 - 2002 Children’s Hospital of Wisconsin, Tumor Board1998 - 1999 Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Director1998 - 1999 House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Chairman

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Bryce A. Kerlin

Contact Information

  • Call us at:
  • (614) 722-3550
  • Fax us at:
  • (614) 722-3369
  • PediatricsHematology & Oncology700 Children’s DrColumbus, OH 43205 (map)

Learn more about Bryce A. Kerlin

Biography

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine. Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots. Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Biography

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine. Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots. Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Biography

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine. Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots. Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine. Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots. Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Bryce Kerlin, MD, is a principal investigator in the Center for Clinical & Translational Research in the Abigail Wexner Research Institute at Nationwide Children’s Hospital. Dr. Kerlin is also director of the Joan Fellowship in Pediatric Hemostasis-Thrombosis at Nationwide Children’s Hospital, an attending physician in the Division of Pediatric Hematology/Oncology/BMT and a professor of Pediatrics at The Ohio State University College of Medicine.

Dr. Kerlin’s research is focused on the translational epidemiology of pediatric thrombosis, focusing on the clarification of biomarkers and clinical features linked to thrombosis, especially in pediatric kidney disease. He actively participates in clinical trials for new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease and blood clots.

Dr. Kerlin earned his Bachelor of Science degree from Purdue University and his medical degree from the Medical College of Wisconsin. He trained in Pediatrics at Phoenix Children’s Hospital, Pediatric Hematology/Oncology at Children’s Hospital of Wisconsin and Coagulation Physiology at the Blood Research Institute (Milwaukee). Dr. Kerlin led the Hemophilia Treatment Center at Rady Children’s Hospital where he was also an assistant professor of Pediatrics at the University of California, San Diego (UCSD) School of Medicine before joining the faculty at Nationwide Children’s in 2004.

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Patient Care

Locations

Main Campus of Nationwide Children’s Hospital

Locations

Main Campus of Nationwide Children’s Hospital

Locations

Main Campus of Nationwide Children’s Hospital

Locations

Main Campus of Nationwide Children’s Hospital

  • Main Campus of Nationwide Children’s Hospital

Academic and Clinical Areas

Pediatric Hemostasis-Thrombosis Fellowship

Program Director

Hemostasis and Thrombosis Center

Physician Team

Hematology/Oncology & BMT

Physician Team

Center for Clinical and Translational Research

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Academic and Clinical Areas

Pediatric Hemostasis-Thrombosis Fellowship

Program Director

Hemostasis and Thrombosis Center

Physician Team

Hematology/Oncology & BMT

Physician Team

Center for Clinical and Translational Research

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Academic and Clinical Areas

Pediatric Hemostasis-Thrombosis Fellowship

Program Director

Hemostasis and Thrombosis Center

Physician Team

Hematology/Oncology & BMT

Physician Team

Center for Clinical and Translational Research

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

Pediatric Hemostasis-Thrombosis Fellowship

Program Director

Hemostasis and Thrombosis Center

Physician Team

Hematology/Oncology & BMT

Physician Team

Center for Clinical and Translational Research

Principal Investigator

Hematology, Oncology and BMT Fellowship

Faculty

Primary Department

Pediatrics

Primary Section

Hematology & Oncology

  • Pediatric Hemostasis-Thrombosis Fellowship
  • Program Director
  • Hemostasis and Thrombosis Center
  • Physician Team
  • Hematology/Oncology & BMT
  • Physician Team
  • Center for Clinical and Translational Research
  • Principal Investigator
  • Hematology, Oncology and BMT Fellowship
  • Faculty
  • Primary Department
  • Pediatrics
  • Primary Section
  • Hematology & Oncology

Awards, Honors & Organizations

Listed, Best Doctors in America

Awards, Honors & Organizations

Listed, Best Doctors in America

Awards, Honors & Organizations

Listed, Best Doctors in America

Listed, Best Doctors in America

  • Listed, Best Doctors in America

Research

Lab(s)

Center for Clinical and Translational Research

Publications

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Research

Lab(s)

Center for Clinical and Translational Research

Publications

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Research

Lab(s)

Center for Clinical and Translational Research

Publications

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Lab(s)

Center for Clinical and Translational Research

Publications

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Lab(s)

Center for Clinical and Translational Research

                  Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

                


                  Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;  

                


                  Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

                


                  Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

                


                  Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

                


                  Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;  

                


                  Kaur D, Kerlin BA, Stanek JR, O'Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

                


                  Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

                


                  Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

                


                  Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

                


                  Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

                


                  Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

                


                  Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

                


                  Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;  

                


                  Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

                


                  Kumar R, Harsh K, Saini S, O'Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

                


                  Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O'Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

                


                  Drayton Jackson M, O'Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;  

                


                  Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D'alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;  

                


                  Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;  

                


                  Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

View More Publications

Lab(s)

Center for Clinical and Translational Research

  • Center for Clinical and Translational Research

  • Medipally A, Xiao M, Biederman L, Satoskar AA, Ivanov I, Rovin B, Parikh S, Kerlin BA, Brodsky SV. Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity. Physiol Rep. 2022 Aug; 10: e15343.

  • Kumar R, Dunn A, Schneiderman JE, Gonzales A, Bouskill V, Widener P, Stanek J, Pluthero FG, Waller A, Tarango C, Ahuja S, Kerlin BA, Kahr WH, Rand ML, Lillicrap D, Carcao M. Moderate-intensity aerobic exercise versus desmopressin in adolescent males with mild hemophilia A: a randomized trial. Blood. 2022 Jul 15;

  • Bryant C, Rask G, Waller AP, Webb A, Galdino-Pitta MR, Amato AA, Cianciolo R, Govindarajan R, Becknell B, Kerlin BA, Neves FAR, Fornoni A, Agrawal S. Selective modulator of nuclear receptor PPAR? with reduced adipogenic potential ameliorates experimental nephrotic syndrome. iScience. 2022 Apr 15; 25: 104001.

  • Poulsen LH, Kerlin BA, Castaman G, Molinari AC, Menegatti M, Nugent D, Dey S, Garly ML, Carcao M. Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence. Res Pract Thromb Haemost. 2022 Feb; 6: e12628.

  • Rodriguez V, Stanek J, Kerlin BA, Dunn AL. Andexanet Alfa Versus Prothrombin Complex Concentrates/Blood Products as Apixaban/Rivaroxaban Reversal Agents: A Survey Among Pediatric Hematologists. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221078842.

  • Giver J, Dunn AL, Sankar A, Stanek J, Monda K, Canini J, Kerlin BA, Rodriguez V. Drive-through Anticoagulation Clinic During The COVID-19 Pandemic. J Nurse Pract. 2021 Sep 8;

  • Kaur D, Kerlin BA, Stanek JR, O’Brien SH. Use of electronic self-administered bleeding assessment tool in diagnosis of paediatric bleeding disorders. Haemophilia. 2021 Sep; 27: 710-716.

  • Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121: 1079-1086.

  • Waller AP, Troost JP, Parikh SV, Wolfgang KJ, Rovin BH, Nieman MT, Smoyer WE, Kretzler M, Kerlin BA, NEPTUNE Investigators.. Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy. Thromb Res. 2021 May; 201: 50-59.

  • Agrawal S, Brier ME, Kerlin BA, Smoyer WE, Pediatric Nephrology Research Consortium.. Plasma Cytokine Profiling to Predict Steroid Resistance in Pediatric Nephrotic Syndrome. Kidney Int Rep. 2021 Mar; 6: 785-795.

  • Han X, Nieman MT, Kerlin BA. Protease-activated receptors: An illustrated review. Res Pract Thromb Haemost. 2021 Jan; 5: 17-26.

  • Wang TF, Waller AP, Lin E, Wei L, Bartosic A, Riedl K, Kerlin BA. A pilot randomized trial of atorvastatin as adjunct therapy in patients with acute venous thromboembolism. Blood Coagul Fibrinolysis. 2021 Jan 1; 32: 16-22.

  • Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulyte Trakymiene S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. Thromb Res. 2020 Mar 9; 189: 96-101.

  • Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int. 2019 Dec 24;

  • Woods GM, Boulet SL, Texter K, Yates AR, Kerlin BA. Venous thromboembolism in chronic pediatric heart disease is associated with substantial health care burden and expenditures. Res Pract Thromb Haemost. 2019 Jul; 3: 372-382.

  • Kumar R, Harsh K, Saini S, O’Brien SH, Stanek J, Warren P, Giver J, Go MR, Kerlin BA. Treatment-Related Outcomes in Paget-Schroetter Syndrome-A Cross-Sectional Investigation. J Pediatr. 2019 Apr; 207: 226-232.e1.

  • Woods GM, Pillay Smiley N, Stanek J, Kahwash S, Kerlin BA, O’Brien SH. Variation in Platelet Delta Granules Over Time in Young Women Undergoing Evaluation for Heavy Menstrual Bleeding. Pediatr Dev Pathol. 2019 Mar-Apr; 22: 123-127.

  • Drayton Jackson M, O’Brien SH, Stanek J, Dunn AL, Kerlin BA. Inpatient Health Care Utilization in Children With Hemophilia Before and After the Joint Outcome Study Publication. J Pediatr Hematol Oncol. 2018 Oct 18;

  • Carpenter SL, Goldman J, Sherman AK, Selewski DT, Kallash M, Tran CL, Seamon M, Katsoufis C, Ashoor I, Hernandez J, Supe-Markovina K, D’alessandri-Silva C, DeJesus-Gonzalez N, Vasylyeva TL, Formeck C, Woll C, Gbadegesin R, Geier P, Devarajan P, Smoyer WE, Kerlin BA, Rheault MN. Association of infections and venous thromboembolism in hospitalized children with nephrotic syndrome. Pediatr Nephrol. 2018 Sep 7;

  • Durda MA, Wolberg AS, Kerlin BA. State of the art in factor XIII laboratory assessment. Transfus Apher Sci. 2018 Aug 4;

  • Carcao M, Altisent C, Castaman G, Fukutake K, Kerlin BA, Kessler C, Lassila R, Nugent D, Oldenburg J, Garly ML, Rosholm A, Inbal A. Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency. Thromb Haemost. 2018 Mar; 118: 451-460.

Education

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

Education

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

Education

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

Date of Appointment at Nationwide Children’s Hospital: 12/31/2004

Board Certifications

Pediatric Hematology Oncology

Fellowship

Medical College of Wisconsin

Date Completed: 06/30/2002

Residency

Phoenix Children’s Hospital

Date Completed: 06/30/1999

Internship

Phoenix Children’s Hospital

Date Completed: 06/30/1997

Medical School

Medical College of Wisconsin

Date Completed: 05/18/1996

  • Pediatric Hematology Oncology

Professional Experience

2005 - Present Nationwide Children’s Hospital, Director of Hematology2004 - Present Nationwide Children’s Hospital Hemophilia & Bleeding Disorders Program, Director2004 - Present Ohio Bleeding Disorders Council, Board Member2004 - Present Nationwide Children’s Hospital, Pharmacy & Therapeutics2004 - Present Nationwide Children’s Hospital, Tumor Board2004 - 2004 Children’s Hospital of San Diego, Pharmacy & Therapeutics Committee2002 - 2004 San Diego Regional Pediatric Hemophilia Program, Director2002 - 2004 Children’s Hospital of San Diego, Tumor Board2002 - 2004 Children’s Hospital of San Diego, Cancer Committee2002 - 2004 Children’s Hospital of San Diego, Transfusion Medicine Committee2002 - 2004 Hemophilia Association of San Diego County, Medical Director1999 - 2002 Children’s Hospital of Wisconsin, Tumor Board1998 - 1999 Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Director1998 - 1999 House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Chairman

Professional Experience

2005 - Present Nationwide Children’s Hospital, Director of Hematology2004 - Present Nationwide Children’s Hospital Hemophilia & Bleeding Disorders Program, Director2004 - Present Ohio Bleeding Disorders Council, Board Member2004 - Present Nationwide Children’s Hospital, Pharmacy & Therapeutics2004 - Present Nationwide Children’s Hospital, Tumor Board2004 - 2004 Children’s Hospital of San Diego, Pharmacy & Therapeutics Committee2002 - 2004 San Diego Regional Pediatric Hemophilia Program, Director2002 - 2004 Children’s Hospital of San Diego, Tumor Board2002 - 2004 Children’s Hospital of San Diego, Cancer Committee2002 - 2004 Children’s Hospital of San Diego, Transfusion Medicine Committee2002 - 2004 Hemophilia Association of San Diego County, Medical Director1999 - 2002 Children’s Hospital of Wisconsin, Tumor Board1998 - 1999 Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Director1998 - 1999 House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Chairman

Professional Experience

2005 - Present Nationwide Children’s Hospital, Director of Hematology2004 - Present Nationwide Children’s Hospital Hemophilia & Bleeding Disorders Program, Director2004 - Present Ohio Bleeding Disorders Council, Board Member2004 - Present Nationwide Children’s Hospital, Pharmacy & Therapeutics2004 - Present Nationwide Children’s Hospital, Tumor Board2004 - 2004 Children’s Hospital of San Diego, Pharmacy & Therapeutics Committee2002 - 2004 San Diego Regional Pediatric Hemophilia Program, Director2002 - 2004 Children’s Hospital of San Diego, Tumor Board2002 - 2004 Children’s Hospital of San Diego, Cancer Committee2002 - 2004 Children’s Hospital of San Diego, Transfusion Medicine Committee2002 - 2004 Hemophilia Association of San Diego County, Medical Director1999 - 2002 Children’s Hospital of Wisconsin, Tumor Board1998 - 1999 Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Director1998 - 1999 House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Chairman

2005 - Present Nationwide Children’s Hospital, Director of Hematology2004 - Present Nationwide Children’s Hospital Hemophilia & Bleeding Disorders Program, Director2004 - Present Ohio Bleeding Disorders Council, Board Member2004 - Present Nationwide Children’s Hospital, Pharmacy & Therapeutics2004 - Present Nationwide Children’s Hospital, Tumor Board2004 - 2004 Children’s Hospital of San Diego, Pharmacy & Therapeutics Committee2002 - 2004 San Diego Regional Pediatric Hemophilia Program, Director2002 - 2004 Children’s Hospital of San Diego, Tumor Board2002 - 2004 Children’s Hospital of San Diego, Cancer Committee2002 - 2004 Children’s Hospital of San Diego, Transfusion Medicine Committee2002 - 2004 Hemophilia Association of San Diego County, Medical Director1999 - 2002 Children’s Hospital of Wisconsin, Tumor Board1998 - 1999 Resident as Teacher Program; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Director1998 - 1999 House Staff Social Committee; Phoenix Children’s Hospital/Maricopa Medical Center Pediatric Residency Program, Chairman

2005 - Present Nationwide Children’s Hospital, Director of Hematology

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Contact Information

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Pediatrics

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)

Call us at: (614) 722-3550

Fax us at: (614) 722-3369

                    Hematology & Oncology700 Children's DrColumbus, OH 43205 (map)
  • Call us at:
  • (614) 722-3550
  • Fax us at:
  • (614) 722-3369
  • Hematology & Oncology700 Children’s DrColumbus, OH 43205 (map)